US007547759B2

(12) **United States Patent**
Ioannides et al.

(10) **Patent No.: US 7,547,759 B2**
(45) **Date of Patent: Jun. 16, 2009**

(54) **INDUCTION OF TUMOR IMMUNITY BY VARIANTS OF FOLATE BINDING PROTEIN**

(75) Inventors: **Constantin G. Ioannides**, Houston, TX (US); **George E. Peoples, Jr.**, Fulton, MD (US)

(73) Assignees: **Board of Regents, The University of Texas System**, Austin, TX (US); **Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.**, Rockville, MD (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/094,097**

(22) Filed: **Mar. 8, 2002**

(65) **Prior Publication Data**

US 2003/0185840 A1 Oct. 2, 2003

Related U.S. Application Data

(60) Provisional application No. 60/274,676, filed on Mar. 9, 2001.

(51) **Int. Cl.**
C07K 17/00 (2006.01)

(52) **U.S. Cl.** **530/328**; 530/300; 530/350

(58) **Field of Classification Search** 530/300, 530/328, 350, 327, 326, 325, 324; 514/2, 514/15; 424/185.1, 277.1
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,830,755	A	11/1998	Nishimura et al.	
5,846,538	A	12/1998	Cheever et al.	
6,153,430	A *	11/2000	Pastan et al.	435/325
6,514,942	B1 *	2/2003	Ioannides et al.	514/15
2003/0027766	A1 *	2/2003	Ioannides et al.	514/13
2003/0077248	A1 *	4/2003	Moriarty et al.	424/85.2

OTHER PUBLICATIONS

Greenspan et al., (Nat Biotechnol. Oct. 1999;17 (10) :936-937).*
Yu et al. (Mol Med. Mar. 2002; 8 (3):137-148).*
McCoullough et al. (ILAR J. 2005; 46 (3): 230-240).*
Bowie et al. (Science. 1990; 257: 1306-1310).*
Holmes (Expert Opinion on Investigational Drugs. 2001, 10: 511-519).*
Huard et al. (Int. Immunol. 1997; 9 (11):1701-1707).*
Fisk et al. (J. Immunother. Emphasis Tumor Immunol. Nov. 1995: 18 (4): 197-209).*
Ruppert et al. (Cell. Sep. 10, 1993; 74 (5): 929-937).*
Valmori et al. (J. Immunol. 1998; 163: 6956-6962).*
Guichard et al. (J. Med. Chem. 2000; 43: 3803-3808).*
Schirle et al. (J. Immunol. Methods. 2001; 257: 1-16).*
Anderson et al. (Tissue Antigens. Jun. 2000; 55 (6): 519-531).*
Feltkamp et al. (Mol. Immunol. Dec. 1994; 31 (18): 1391-1401).*
van der Burg et al. (J. Immunol. May 1, 1996; 156 (9): 3308-3314).*
Valmori et al. (Journal of Immunology. 1998; 160: 1750-1758).*
Campbell et al. (Cancer Res. Oct. 1991; 51 (19): 5329-5338).*
Yamshchikov, et al (Clinical Cancer Research. 2001; 7: 909s-916s).*
Bodey et al. (Anticancer Research 20: 2665-2676, 2000).*
Ezzell (Journal of NIH Research 7: 46-49, 1995).*
Spitler (Cancer Biotherapy 10: 1-3, 1995).*
Lee et al. (Journal of Immunology 163:6292-6300, 1999).*
Zaks et al. (Cancer Research 58: 4902-4908, 1998).*
Gao et al. (Journal of Immunotherapy 23:643-653, 2000).*
Lu et al. (J. Controlled Release. 2003; 91; 17-29).*
Lollini et al. (Trends in Immunology. Feb. 2003; 24 (2): 62-66).*
Gura (Science. 1997; 278:1041-1042).*
Saijo et al. (Cancer Sci. Oct. 2004; 95 (10): 772-776).*
Forni et al. (Int. Immunopharmacol. 2003; 3: 1151-1158).*
Skolnick et al. (Trends in Biotechnology 2000; 18 (1): 34-39).*
De Plaen et al. (Immunogenetics. 1994; 40:360-369).*
Li, Pei Yong, et al.; Local Concentration of Folate Binding Protein GP38 in Sections of Human Ovarian Carcinoma by In Vitro Quantitative Autoradiography; J Nucl Med 1996; 37:665-672.
Ioannides, Constantin G., et al.; Lymphocytes Infiltrating Ovarian Malignant Ascites: Modulation of IL-2-Induced Proliferation by IL-4 and of Selective Increase in CD8+ T Cells by TNF-a; Lymphokine and Cytokine Research, vol. 10 (4), 1991, pp. 307-315.
Ioannides, Constantin G., et al.; Induction of interleukin—2 receptor by tumor necrosis factor a on cultured ovarian tumor-associated lymphocytes; Cancer Immunol Immunother (1992) 35:83-91.
Ioannides, Constantin G., et al.; Cytotoxic T Cells from Ovarian Malignant Tumors Can Recognize Polymorphic Epithelial Mucin Core Peptides; The Journal of Immunology, vol. 151 (7), pp. 3693-3703, Oct. 1, 1993.
Falk, Kirsten, et al.; Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules; Nature, vol. 351, pp. 290-296, May 23, 1991.
Alexander, Richard B., et al.; Adoptively Transferred Tumor-Infiltrating Lymphocytes Can Cure Established Metastatic Tumor in Mice and Persist Long-Term In Vivo as Functional Memory T Lymphocytes; Journal of Immunotherapy 10:389-397, 1991.
Bednarek, Maria A., et al.; Soluble HLA-A2.1 restricted peptides that are recognized by influenza virus specific cytotoxic T lymphocytes; Journal of Immunological Methods, 139 (1991) 41-47.
Buelow, Roland, et al.; Localization of the immunologic activity in the superantigen staphylococcal enterotoxin B using truncated recombinant fusion proteins; The Journal of Immunology, vol. 148 (1), pp. 1-6, Jan. 1, 1992.
Pietersz, G. A., et al.; Generation of Cellular Immune Responses to Antigenic Tumor Peptides; CMLS Cellular and Molecular Life Sciences 57 (2000) 290-310.
Pardoll, Drew M.; Therapeutic Vaccination for Cancer; Clinical Immunology, vol. 95, No. 1, April, pp. S44-S62. 2000.
Rosenberg, Steven A., The Identification of Cancer Antigens: Impact on the Development of Cancer Vaccines; The Cancer Journal; S142-S149.

(Continued)

Primary Examiner—Stephen L Rawlings
(74) *Attorney, Agent, or Firm*—Fulbright & Jaworski, LLP

(57) **ABSTRACT**

The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by energy, as in unresponsiveness.

2 Claims, 6 Drawing Sheets